FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074989651> ?p ?o ?g. }

• W2074989651 endingPage "1282" @default.
• W2074989651 startingPage "1267" @default.
• W2074989651 abstract "Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double-blind, placebo-controlled, Phase 3 study evaluated the efficacy and safety of canagliflozin as an add-on to metformin plus sulphonylurea in patients with T2DM.Patients (N = 469) received canagliflozin 100 or 300 mg or placebo once daily during a 26-week core period and a 26-week extension. Prespecified primary end-point was change in HbA1c at 26 weeks. Secondary end-points included change in HbA1c at week 52 as well as proportion of patients achieving HbA1c < 7.0%, change in fasting plasma glucose (FPG) and systolic blood pressure, and per cent change in body weight, high-density lipoprotein cholesterol, and triglycerides (weeks 26 and 52).HbA1c was significantly reduced with canagliflozin 100 and 300 mg vs. placebo at week 26 (-0.85%, -1.06%, and -0.13%; p < 0.001); these reductions were maintained at week 52 (-0.74%, -0.96%, and 0.01%). Both canagliflozin doses reduced FPG and body weight vs. placebo at week 26 (p < 0.001) and week 52. Overall adverse event (AE) rates were similar across groups over 52 weeks, with higher rates of genital mycotic infections and osmotic diuresis-related AEs seen with canagliflozin vs. placebo; these led to few discontinuations. Increased incidence of documented, but not severe, hypoglycaemia episodes was seen with canagliflozin vs. placebo.Canagliflozin improved glycaemic control, reduced body weight, and was generally well tolerated in T2DM patients on metformin plus sulphonylurea over 52 weeks." @default.
• W2074989651 created "2016-06-24" @default.
• W2074989651 creator A5002858323 @default.
• W2074989651 creator A5022459640 @default.
• W2074989651 creator A5031542137 @default.
• W2074989651 creator A5035285423 @default.
• W2074989651 creator A5047195042 @default.
• W2074989651 creator A5053469409 @default.
• W2074989651 creator A5061286574 @default.
• W2074989651 creator A5061317385 @default.
• W2074989651 creator A5076983296 @default.
• W2074989651 creator A5083959015 @default.
• W2074989651 creator A5089208115 @default.
• W2074989651 date "2013-10-13" @default.
• W2074989651 modified "2023-10-17" @default.
• W2074989651 title "Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial" @default.
• W2074989651 cites W1968236091 @default.
• W2074989651 cites W1973240292 @default.
• W2074989651 cites W1976567448 @default.
• W2074989651 cites W1994832750 @default.
• W2074989651 cites W1997018189 @default.
• W2074989651 cites W2008443217 @default.
• W2074989651 cites W2021988691 @default.
• W2074989651 cites W2031333151 @default.
• W2074989651 cites W2038270027 @default.
• W2074989651 cites W2038953694 @default.
• W2074989651 cites W2042129134 @default.
• W2074989651 cites W2043121816 @default.
• W2074989651 cites W2068171948 @default.
• W2074989651 cites W2077038286 @default.
• W2074989651 cites W2081510795 @default.
• W2074989651 cites W2084511068 @default.
• W2074989651 cites W2109728760 @default.
• W2074989651 cites W2114031829 @default.
• W2074989651 cites W2114276479 @default.
• W2074989651 cites W2120919346 @default.
• W2074989651 cites W2122077393 @default.
• W2074989651 cites W2123984464 @default.
• W2074989651 cites W2125028944 @default.
• W2074989651 cites W2129449971 @default.
• W2074989651 cites W2130570549 @default.
• W2074989651 cites W2133469996 @default.
• W2074989651 cites W2137107263 @default.
• W2074989651 cites W2138290933 @default.
• W2074989651 cites W2140785809 @default.
• W2074989651 cites W2152397610 @default.
• W2074989651 cites W2158482469 @default.
• W2074989651 cites W2167984652 @default.
• W2074989651 cites W2172193326 @default.
• W2074989651 cites W2499426752 @default.
• W2074989651 cites W2554729258 @default.
• W2074989651 cites W4235717978 @default.
• W2074989651 doi "https://doi.org/10.1111/ijcp.12322" @default.
• W2074989651 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4282288" @default.
• W2074989651 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24118688" @default.
• W2074989651 hasPublicationYear "2013" @default.
• W2074989651 type Work @default.
• W2074989651 sameAs 2074989651 @default.
• W2074989651 citedByCount "271" @default.
• W2074989651 countsByYear W20749896512014 @default.
• W2074989651 countsByYear W20749896512015 @default.
• W2074989651 countsByYear W20749896512016 @default.
• W2074989651 countsByYear W20749896512017 @default.
• W2074989651 countsByYear W20749896512018 @default.
• W2074989651 countsByYear W20749896512019 @default.
• W2074989651 countsByYear W20749896512020 @default.
• W2074989651 countsByYear W20749896512021 @default.
• W2074989651 countsByYear W20749896512022 @default.
• W2074989651 countsByYear W20749896512023 @default.
• W2074989651 crossrefType "journal-article" @default.
• W2074989651 hasAuthorship W2074989651A5002858323 @default.
• W2074989651 hasAuthorship W2074989651A5022459640 @default.
• W2074989651 hasAuthorship W2074989651A5031542137 @default.
• W2074989651 hasAuthorship W2074989651A5035285423 @default.
• W2074989651 hasAuthorship W2074989651A5047195042 @default.
• W2074989651 hasAuthorship W2074989651A5053469409 @default.
• W2074989651 hasAuthorship W2074989651A5061286574 @default.
• W2074989651 hasAuthorship W2074989651A5061317385 @default.
• W2074989651 hasAuthorship W2074989651A5076983296 @default.
• W2074989651 hasAuthorship W2074989651A5083959015 @default.
• W2074989651 hasAuthorship W2074989651A5089208115 @default.
• W2074989651 hasBestOaLocation W20749896512 @default.
• W2074989651 hasConcept C126322002 @default.
• W2074989651 hasConcept C134018914 @default.
• W2074989651 hasConcept C142724271 @default.
• W2074989651 hasConcept C197934379 @default.
• W2074989651 hasConcept C204787440 @default.
• W2074989651 hasConcept C27081682 @default.
• W2074989651 hasConcept C2777180221 @default.
• W2074989651 hasConcept C2777451236 @default.
• W2074989651 hasConcept C2780323712 @default.
• W2074989651 hasConcept C2910068830 @default.
• W2074989651 hasConcept C555293320 @default.
• W2074989651 hasConcept C71924100 @default.
• W2074989651 hasConcept C90924648 @default.
• W2074989651 hasConceptScore W2074989651C126322002 @default.
• W2074989651 hasConceptScore W2074989651C134018914 @default.
• W2074989651 hasConceptScore W2074989651C142724271 @default.

• next